News
GlobalData on MSN4d
Sarepta Therapeutics to cut 500 jobs amid restructuring
The company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.
The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...
Sarepta Therapeutics will cut 500 jobs and add a serious warning on the label of its muscle-disorder gene therapy Elevidys, the drugmaker said on Wednesday, following the recent deaths of two patients ...
British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March ...
The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.
Shares of Sarepta Therapeutics declined 17% in early trading on Friday after another patient who had received an experimental ...
The company will pause several gene therapy development programs, for which it intends to seek partners and other strategic alternatives.
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback